Phase III CheckMate-743 study of Opdivo and Yervoy meets primary OS endpoint in mesothelioma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

CheckMate -743, a phase III trial evaluating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) in previously untreated malignant pleural mesothelioma met its primary endpoint of overall survival.

Bristol-Myers Squibb sponsors both drugs.

Based on a prespecified interim analysis conducted by the independent data monitoring committee, Opdivo in combination with Yervoy resulted in a statistically significant and clinically meaningful improvement in OS compared to chemotherapy (pemetrexed and cisplatin or carboplatin).

The safety profile of Opdivo plus Yervoy observed in the trial reflects the known safety profile of the combination.

“These topline results from the CheckMate-743 trial demonstrate the potential of Opdivo plus Yervoy in previously untreated patients with malignant pleural mesothelioma, and is another example of the established efficacy and safety of the dual immunotherapy combination seen in multiple tumor types,” Sabine Maier, development lead of Thoracic Cancers at BMS, said in a statement.

CheckMate-743 is an open-label, multi-center, randomized phase III trial evaluating Opdivo plus Yervoy compared to chemotherapy (pemetrexed and cisplatin or carboplatin) in patients with previously untreated malignant pleural mesothelioma. The primary endpoint of the trial was OS. Secondary endpoints included objective response rate, disease control rate, progression-free survival, and efficacy measures according to PD-L1 expression level.

Table of Contents

YOU MAY BE INTERESTED IN

When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.

Login